Safety evaluation of enoxaparin in currently approved indications.

Item

http://www.wikidata.org/entity/Q37622250

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Safety evaluation of enoxaparin in currently approved indications.

@en

Safety evaluation of enoxaparin in currently approved indications.

@nl

type

Item

label

Safety evaluation of enoxaparin in currently approved indications.

@en

Safety evaluation of enoxaparin in currently approved indications.

@nl

prefLabel

Safety evaluation of enoxaparin in currently approved indications.

@en

Safety evaluation of enoxaparin in currently approved indications.

@nl

P1476

Safety evaluation of enoxaparin in currently approved indications.

@en

P2093

Nicolas Meneveau

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

Bivalirudin for patients with acute coronary syndromes

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

P304

745-754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740330903352498

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19860536

http://www.w3.org/2001/XMLSchema#string